BioLineRx (BLRX) Posts Q3 Loss of 1c/ADS

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.01), $0.16 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Ready Capital prices $225M in new notes, redeems $350M due 2026
• Jana Partners urges Cooper Companies to replace CEO and explore asset sales